Ovarian cancer diagnosis
- Comprehensive staging in ovarian cancer
- [Expression of CA-125 in ovarian cancer].
- Utilitatea imunohistochimiei în diagnosticul carcinomului ovarian
- Cancer ovarian stage 1,
- The utility of immunohistochemistry in the diagnosis of ovarian carcinoma
- Altchek's Diagnosis and Management of Ovarian Disorders - bebeplanet.ro Ovarian cancer ct scan
Knowing that the diagnosis age for a significant proportion of patients is above 65 years old, for a proper therapeutic conduct and in order to avoid treatment interruptions ovarian cancer diagnosis by toxicity, it was attempted the adjustment of the initial protocole.
In conclusion, the weekly therapeutic scheme is much better tolerated by patients, with a favorable therapeutic response.
Comprehensive staging in ovarian cancer
Keywords ovarian cancer, fragile age, toxicity, comorbidities Rezumat Vârsta înaintată a pacientelor diagnosticate cu cancer ovarian avansat prezintă un impact major asupra prognosticului, întrucât tratamentul standard de primă linie, carboplatin-paclitaxel administrate la fiecare trei săptămâni, este deseori greu de tolerat din cauza efectelor secundare pronunţate, conducând la pierderea intensităţii dozei sau chiar la întreruperea tratamentului.
Ştiind că vârsta de diagnosticare pentru un procent semnificativ de paciente este mai mare de 65 de ani, pentru o conduită terapeutică adecvată şi pentru a evita amânările tratamentului datorate toxicităţilor, s-a încercat adaptarea protocolului iniţial.
În concluzie, ovarian cancer diagnosis de administrare săptămânală este mult mai bine tolerată de paciente, cu un răspuns terapeutic favorabil.
Cuvinte cheie cancer ovarian vârstă fragilă toxicitate comorbidităţi Ovarian cancer is the main ovarian cancer diagnosis of death by gynecological tumors in Europe. This combination has a high rate of ovarian cancer diagnosis effects in the general population, such as fatigability, hematological and neurological toxicities, which in elderly patients more than 70 years old can be considered unacceptable, leading to the premature discontinuation ovarian cancer diagnosis treatment, age itself being considered an unfavorable prognosis factor 3.
In the past 12 ovarian cancer diagnosis, many studies and clinical trials tried to assess the possibility of administering a tailor-made therapy in elderly patients diagnosed with advanced stage ovarian cancer.
For this category of patients, the standard treatment can induce an increased toxicity risk, thus other options can be used in current practice.
[Expression of CA-125 in ovarian cancer].
One of the possibilities is the monotherapy with carboplatin. The result were interpreted as ovarian cancer diagnosis. Base on this score, there were identified the patients at risk for developing severe toxicities, the direct consequence being the early discontinuation of the treatment, repetead unplanned hospitalizations, and the aggravation of associated pathologies.
This study was performed to evaluate the clinical risk profile of patients with ovarian tumors who were surgically treated, measuring the survival rate at 5 years. Furthermore, the surgical treatment by TNM stages was achieved, measuring the survival rate after five years of follow-up.
Geriatric vulnerability scale The phase II multicentric MITO-5 study analyzed the tolerability of combined paclitaxel-carboplatin therapy with an weekly administration in patients with fragile age, between January and Mayin a number of 26 patients enrolled. The carboplatin dose was calculated according to Calvert formula 6administered in ml of normal saline, in 30 minutes.
The purpose of this paper is to quantify the incidence of different histological types of ovarian tumors and to demonstrate the clinical importance of an effective screening program, considering the paucisymptomatic nature of this pathology. The incidence of ovarian epithelial tumors varied across age groups, our study group including women aged between 34 and 64 years old.
The geriatric aspect was assessed using ADL and IADL, all comorbidities being noted, the main ones being arterial hypertension, diabet mellitus, osteoporosis and arthritis. Table 1.
Utilitatea imunohistochimiei în diagnosticul carcinomului ovarian
Patients compliance to treatment The final results were positively reported to the study design, only three cases of severe ovarian cancer diagnosis being described out of the 26 treated patients one case of atrial fibrillation in an already diagnosed patient with congestive heart failure, a case of grade-3 hepatic toxicity, and a case of neutropenia and prolonged trombocytopenia.
The estimated median of progression-free survival was In conclusion, the weekly administration had a more reduced toxic profile compared to standard treatment scheme, which makes this treatment adjustment more appropriate for fragile patients diagnosed with advanced ovarian cancer.
What does the future hold for? Study arm B: carboplatin in monotherapy AUC 5 or 6, in every three weeks.
Cancer ovarian stage 1,
As secondary outcome, there are analyzed: the therapeutic stategies, the overall survival, the progression-free survival, the quality of life, the safety and tolerability, and markers related to age. The results of the study will be published in Conflict of interests: The author declares no conflict of interests.
Survival for ovarian cancer in Europe: the across-country variation did not shrink ovarian cancer diagnosis the past decade. Acta Oncol.
Gynecologic Oncology Group: phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel ovarian cancer diagnosis patients with optimally resected stage III ovarian cancer: a gynecologic oncology group stdy. J Clin Oncol.
The utility of immunohistochemistry in the diagnosis of ovarian carcinoma
Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. Crit Rev Oncol Hematol.
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial.
Ann Ovarian cancer diagnosis. Carboplatin dosage: prospect of evaluation of a simple formula based on renal function.
Altchek's Diagnosis and Management of Ovarian Disorders - bebeplanet.ro Ovarian cancer ct scan
Rustin GJS. Use of CA to assess response to new agents in ovarian cancer trials.
Stan Doxorubicina lipozomală pegilată PLD este o antraciclină utilizată în tratamentul cancerului ovarian. Deşi prezintă mai puţină cardiotoxicitate Dana Lucia Stănculeanu Tratamentul cancerului de sân cuprinde o varietate de agenți chimioterapici, de la clasicele citostatice, precum antraciclinele, ciclofosfamida, ta